Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: A randomized, open-label, crossover study

Clinical Therapeutics

Volumn 32, Issue 12, 2010, Pages 2074-2087

  Darwish, Mona ^a   Kirby, Mary ^a   D'Andrea, Denise M ^a   Yang, Ronghua ^a   Hellriegel, Edward T ^a   Robertson Jr , Philmore ^a  

^a CEPHALON INC   (United States)

Author keywords

Armodafinil; Modafinil; Obstructive sleep apnea; Pharmacokinetics; Systemic exposure

Indexed keywords

ARMODAFINIL; MODAFINIL;

ADULT; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BIOEQUIVALENCE; BLOOD PRESSURE; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GINGIVA BLEEDING; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; POSITIVE END EXPIRATORY PRESSURE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP APNEA SYNDROME; SOMNOLENCE; THORAX PAIN; XEROSTOMIA;

AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; SLEEP APNEA, OBSTRUCTIVE; THERAPEUTIC EQUIVALENCY;

EID: 78649620604     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.11.009     Document Type: Article

References (20)

1. Provigil (modafinil) tablets [prescribing information] 2010, Cephalon, Inc, Frazer, Pa.
2. Nuvigil (armodafinil) tablets [prescribing information] 2010, Cephalon, Inc, Frazer, Pa.
3. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol. 1999, 39:30-40.
4. Wong YN, King SP, Simcoe D, et al. Open-label, singledose pharmacokinetic study of modafinil tablets: Influence of age and gender in normal subjects. J Clin Pharmacol. 1999, 39:281-288.
5. Wilkinson GR Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. Goodman & Oilman's the Pharmacological Basis of Therapeutics 2001, McGraw-Hill, New York, NY. 10th ed. J.G. Hardman, L.E. Limbird, A. Goodman Gilman (Eds.).
6. Ross EM, Kenakin TP Pharmacodynamics: Mechanisms of drug action and the relationship between drug concentration and effect. Goodman & Oilman's the Pharmacological Basis of Therapeutics 2001, 31-44. McGraw-Hill, New York, NY. 10th ed. J.G. Hardman, L.E. Limbird, A. Goodman Gilman (Eds.).
7. Darwish M, Kirby M, Hellriegel ET, et al. Pharmacokinetic profile of armodafinil in healthy subjects: Pooled analysis of data from three randomized studies. Clin Drug Investig. 2009, 29:87-100.
8. Dinges DF, Arora S, Darwish M, Niebler GE Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin. 2006, 22:159-167.
9. Guideline for good clinical practice, E6(R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 1996, International Conference on Harmonisation, ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline, Accessed September 11, 2009. http://www.ich.org/cache/compo/475-272-1.html#E6.
10. Johns MW A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep 1991, 14:540-545.
11. Robertson P, Hellriegel ET Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003, 42:123-137.
12. Darwish M, Kirby M, Robertson P, Hellriegel ET Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008, 47:61-74.
13. Gibaldi M, Perrier D Noncompartmental analysis based on statistical moment theory. Pharmacokinetics 1982, 409-418. Marcel Dekker, New York, NY. 2nd ed.
14. Guidance for industry: Statistical approaches to establishing bioequivalence US Dept of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research, Accessed August 23, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf.
15. Darwish M, Kirby M, Hellriegel ET Comparison of steady-state plasma concentrations of armodafinil and modafinil late in the day following morning administration: Post hoc analysis of two randomized, doubleblind, placebo-controlled, multipledose studies in healthy male subjects. Clin Drug Investig. 2009, 29:601-612.
16. Darwish M, Kirby M, Hellriegel ET, Robertson P Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal halflives: Analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig. 2009, 29:613-623.
17. Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. RespirMed. 2007, 101:616-627.
18. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: A 12-week, multicenter, doubleblind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther. 2006, 28:689-706.
19. Pack AI, Black JE, Schwartz JR, Matheson JK Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med. 2001, 164:1675-1681.
20. Black JE, Hirshkowitz M Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep. 2005, 28:464-471.